National –
AstraZeneca's vaccine production in Thailand has been approved under Siam Bioscience Company Limited by the Food and Drug Administration (FDA) of Thailand, the company's country president announced today, April 28th.
James Teague, Country President of AstraZeneca (Thailand) Co.Ltd., revealed in a press release that the company's plans to produce its Covid-19 vaccine in Thailand have made significant progress, and the first batch of the vaccine will be ready for delivery to the Thai government in June.
AstraZeneca, together with Siam Bioscience, has also been working as the "regional production hub" to ensure that the distribution will be able to make it to Thailand and another eight countries in Southeast Asia in the same exact month as well.
According to AstraZeneca's statement, each batch of the vaccine undergoes more than 60 quality controls during the manufacture-to-vaccination process. Siam Bioscience has been proved for its world-class vaccine product standard, as known as the Good Manufacturing Address (GMA), ensuring that the products are consistently produced and controlled according to quality standards.
Mr. Teague said: "AstraZeneca and our global manufacturing partners, including Siam Bioscience, are committed to maintaining the highest safety and quality standard of our products. Numerous safety tests and quality control measures are carried out at each step. We are working as quickly as possible to supply the vaccine to the Government of Thailand to overcome the ongoing pandemic."
"We all have the same objective, to get effective vaccines to everybody as quickly as possible but safely. At the core of everything we do is the health and the well-being of Thai people." Mr. Teague concluded.
Inga kommentarer:
Skicka en kommentar